Preclinical findings in mice receiving [177Lu]Lu-PSMA-617 RLT have proven that a higher density of the transmembrane glycoprotein PSMA on prostate cancer cells is associated with increased ligand internalization and treatment efficacy [19]. The gene discussed is FOLH1; the disease is prostate carcinoma.